InvestorsHub Logo
Followers 61
Posts 7531
Boards Moderated 2
Alias Born 02/10/2010

Re: steve2150 post# 43726

Wednesday, 05/08/2024 10:07:14 AM

Wednesday, May 08, 2024 10:07:14 AM

Post# of 43764
Yeah - that's not entirely spelled out in the new Cel-Sci report document. However, I am guessing that they can get enrollment done much more efficiently than they did with that previous trial. Man that was a train-wreck last time with the CRO issues that they had. n

They should be able to get the tumor shrinkage and biomarker data under their belt rapidly. I suspect that they should be able to get enrollment relatively rapidly now as well with the existing supporting data. But survivorship data is just going to take the time to get it done.

They might go fishing for a partnership with a big pharma - or perhaps get a buyout offer on the table? As de-risked as Multikine is at this stage, some big oncology pharma might make 'us' an offer.

“The two most powerful warriors are patience and time.”
- Leo Nikolaevich Tolstoy

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CVM News